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ABSTRACT
Human immunodeficiency virus (HIV) affects about 40 million people world-wide; there
is currently no cure for HIV or Acquired Immunodeficiency Syndrome (AIDS). This paper will
begin by explaining viruses/retroviruses and HIV infection/progression at the molecular, cellular,
and organismal level. Common drug therapy will be mentioned, followed by in-depth
discussions on the processes of three different therapies that combat HIV-1 at either the
molecular, cellular, or organismal level. Once the virus has been integrated in the genome,
antiretroviral therapies (ART) begin. At the molecular level, gene silencing has the power to
essentially “shut down” or “cut out” genes from the integrated proviral genome that therefore
stop its reproduction and transmission to other cells. The machinery discussed will include
CRISPR-CAS9, and short interfering RNA (siRNA). At the cellular level, cytotherapy is
designed to transplant cells for replacement of damaged tissue and/or cells. The mechanisms for
this will include stem cells, human embryonic stem cells (hESCs), umbilical cord blood stem
cells (UCBs), and induced pluripotent stem cells (iPSCs). Symptoms of HIV at the organismal
level are detrimental. Medical marijuana has recently been approved in dozens of states for
HIV/AIDS. Medical marijuanna has positive/beneficial effects on those who suffer with
neuropathy, nausea, lack of appetite, diarrhea, undesired weight loss, depression and/or anxiety,
and ultimately AIDS wasting syndrome from HIV and/or ART drugs. This paper will include not
only a literary review analysis on the matter, but also an interview with someone HIV+ who uses
marijuana as a therapy. This thesis will also include an outlook on the most promising therapies,
HIV preventative medicine/vaccine research, as well as any disadvantages/challenges of the ones
discussed.
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1. INTRODUCTION ON VIRUSES AND RETROVIRUSES.
Viruses are composed of genetic material enclosed in a protein capsule. HIV, like many
other viruses, contains an outer lipid envelope with glycoproteins (see figure 1). Viruses are not
considered cells because they have no biosynthetic pathways or metabolism of their own, but
depend entirely on the cells they infect to survive. After contact with a host cell, the virus will
incorporate its genetic material into the host cell’s genome and hijack its functions, generating
viral genetic material and viral proteins instead of a normal cell’s products. Retroviruses
compose a large group of RNA viruses. They are identified by their unique structure, but mostly
because of their replication strategy (Coffin, Hughes, and Varmus, 1997).
Figure 1- Structure of HIV
Source: Human Immunodeficiency
Virus (HIV) Definition. (n.d.).
Retrieved from
https://aidsinfo.nih.gov/understandin
g-hiv-aids/glossary/325/human-imm
unodeficiency-virus.

The lipid envelope of retroviruses contain glycoproteins, proteins with oligosaccharide
chains attached to the protein. These membrane markers are extremely important in their
pathogenesis since the first step of viral infection is to identify a receptor on the host cell surface
and for the virus to bind to it. In most cases, the first attachment site is a glycan (Banerjee and
Mukhopadhyay, 2016).
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A. THE CENTRAL DOGMA, RETHOUGHT.
The “Central Dogma” states that genetic material moves in one direction. DNA is
transcribed to RNA, and RNA is translated to protein (Watson, 1965). The hallmark of
retroviruses is their replication strategy, reverse transcription of the virion RNA into
double-stranded DNA and the integration of this viral DNA into the host cell genome, due to a
viral encoded polymerase that copies RNA into DNA (Coffin et. al, 1997) (see figure 2).
Figure 2- Modern Central Dogma
Source: Central Dogma. (n.d.).
Retrieved from
http://oregonstate.edu/instruct/bb451
/451material/OutlineMaterials/34Tra
nslation.html.

Viruses like HIV reverse the flow of genetic material, hence the term “retrovirus,” (see
figure 2). Retroviruses can be simple or complex, all retroviruses code for 3 virion proteins. Gag
codes for the virus matrix (p17), capsid, and nucleoprotein structures (p24, p7, p6). Pol codes for
the reverse transcriptase and integrase enzymes. Env c odes for the surface and membrane
components of the protein coat (gp120, gp41). Pro codes for the virion protease. Complex
viruses also code for additional regulatory sequences. Tat (named tax in figure 3), changes the
affinity of the host cells RNA polymerase to the viral promoter (Klaus, 2003). It stimulates
production of transcription of full-length RNA transcripts. Most RNA processing occurs in the
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nucleus, fully spliced mRNA (exons) are transported into the cytoplasm for packaging. Rev
(named rex in figure 3), exports unspliced or partly-spliced mRNA into the cytoplasm, and
through nuclear localization signal (NLS) can target the resulting protein to the nucleus (2003).
HIV is a complex virus.
Figure 3- Genome of a (A)
simple and (B) complex
retrovirus reading frame.
Source: Coffin JM, Hughes
SH, Varmus HE, editors.
Retroviruses. Cold Spring
Harbor (NY): Cold Spring
Harbor Laboratory Press;
1997. The Place of
Retroviruses in Biology.
Available from:
https://www.ncbi.nlm.nih.gov/
books/NBK19382/

There are two strains of HIV, HIV-1 and HIV-2. HIV-2 is a less virulent infection
compared to HIV-1. HIV-1 is responsible for most of the global AIDS pandemic
(Campbell-Yesufu & Gandhi, 2011). Over 1,000 people contract HIV every day in South Africa.
HIV-2 was initially found in West Africa, but has spread to Africa, Europe, and the United
States. Prevalence in West Africa has dropped significantly in recent years, especially among the
youth (Van der Loeff et al, 2006; Da Silva et al, 2008), but still affects about 2 million people.
HIV-1 alone will be considered in this thesis.
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2. INFECTION AT THE MOLECULAR LEVEL
HIV is transmitted through body fluids, such as blood or semen. HIV can also be
transmitted from a mother who has HIV to a child, during pregnancy or breastfeeding. Once in
the body, the HIV replication cycle begins. The lifecycle of viruses have 6 key steps:
Figure 4- Life Cycle of
HIV.
Source: Life Cycle
Definition. (n.d.).
Retrieved from
https://aidsinfo.nih.gov/un
derstanding-hiv-aids/glossa
ry/1596/life-cycle.

A. BINDING
HIV glycoproteins gp120 and gp41 are essential for virus recognition (gp120) and
entrance (gp41) into targeted cells (Fanales-Belasio, Raimondo, Suligoi, and Butto, 2010).
Gp120 binds with both a CD4 glycoprotein (expressed on most T helper cells (T-lymphocytes
and T-cell precursors), monocytes/macrophages, dendritic cells, and microglial cells of the
nervous system) and a chemokine receptor, small proteins that mediate the attraction of immune
cells in an inflammatory response (2010). The chemokine receptor is either CXCR4 or CCR5.
Depending on the chemokine receptor, HIV-1 either has CXCR4 tropism or CCR5 tropism. The
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chemokine receptors on our T-lymphocytes and other cells mentioned are essentially locks which
HIV has the key for. It’s important to note that T cells (like B cells) are vital to the adaptive
immune system, and depletion of immune cells is detrimental to an organism. The gp120 and
gp41 complex changes shape after binding with a CD4 T cell. The shape change, as well as the
double binding with a chemokine receptor elicits a humoral response, as would be with any viral
invasion. However, in HIV infection the humoral response is known to be ineffective to stop
viral propagation because the antibodies produced by most are non-neutralizing, meaning they
recognize viral epitopes (part of the antigen that is recognized by an antibody) that fail to
interfere with the replicative cycle of the virus (Carrillo et al., 2015).
B. FUSION
With a more stable double-attachment, gp41 and the chemokine receptor fuse with the
cell membrane and allow for the entry of the viral capsid (Fanales-Belasio et. al, 2010). The
virus then “uncoats” itself in the cytoplasm, freeing the RNA in the host cell.
C. REVERSE TRANSCRIPTION
Once in the cell, Reverse transcriptase uses the viral RNA to make a single stranded
DNA (SSDNA) and a complementary DNA strand (cDNA) to make double stranded viral DNA
(DSDNA). This conversion allows HIV to enter the CD4 cell’s nucleus and combine with the
host DNA. The rapid rate of HIV evolution is largely attributable to the error-prone nature of
reverse transcriptase, which plays an important role in viral replication yet lacks proofreading
activity (Andrews and Rowland-Jones, 2017).
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 D. INTEGRATION
HIV releases the enzyme integrase, which will bring the viral DSDNA into the nucleus
and integrate the DSDNA into our own DNA as a “provirus.” Once integrated, the provirus can
remain untranscribed until induced.
E. REPLICATION
When induced, DNA polymerase will attach to the provirus sequence and use the host
cell’s machinery to transcribe the DNA, producing viral mRNA which binds to ribosomes to be
translated into HIV proteins. First, small regulatory RNA is translated, followed by larger RNA
that codes for viral enzyme and envelope/coat proteins. These proteins will serve as the building
blocks that will assemble to make more HIV.
F. ASSEMBLY
Synthesized proteins and long HIV RNA move towards the membrane of the CD4 T cell.
The virus is not infectious yet. At this point, HIV slightly buds out of the host cell.
G. RELEASE
Lastly, the immature virus buds out of the host cell. The lipid envelope like most cell
membranes is a phospholipid bilayer. The HIV bilayer is formed by plasma membranes of
previously infected cells in the earlier life cycle ventures of the virus. Carrying both viral and
host glycoproteins helps the virus evade detection from our immune system.The most important
cause behind viral infection is that it has evolved its own sugars and receptors in a way that
mimics or interferes with the host glycan immune response (Banerjee and Mukhopadhyay,
2016). Here, the protease transcribed from the Pro g ene splices the long viral RNA into
sections,
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each including vital genes or enzymes, that will serve as the genome of the new virus. Finally,
the virus is now mature and infectious.
HIV has now hijacked our biosynthetic machinery to make more copies of itself. This
cycle will continue indefinitely.
3. INFECTION AT THE CELLULAR LEVEL
A study done by Doitsh et. al (2010) showed the mechanism for how CD4 T cells are
depleted in hosts remains poorly understood. Isolated human tonsil tissue was infected with
HIV-1. Surprisingly, more than 95% of dying cells were not actively infected, they are
considered “bystander cells.” The study showed that on day 6 of infection, the number of CD4 T
cells were not altered. However, by day 9 the tissue was almost completely absent of CD4 T
cells.
A. CASPASES AND IFI16
Infected HIV cells are brought to the lymph nodes, the “police stations” of our body
along with non-infected CD4 T cells as an immune response. The role of lymph nodes and their
pathology were recognized as important consequences of human immunodeficiency virus (HIV)
infection since the beginning of the HIV epidemic (Dimopoulos, 2017). At this point, HIV
attempts to infect the non-infected CD4 T cells in the lymph nodes. If unsuccessful, incomplete
reverse transcripts accumulate in the cell.
The mass production is detected by the IFI16 sensor, which is on the lookout for rogue
DNA that should not be in our cells. IFI16 is the only mammalian DNA sensor identified that
recognizes both single and double-stranded (DS) DNA (Doitsh & Greene, 2016). IFI16 produces
an inflammasome assembly, caspase 1 activation, and the induction of pyroptosis, a highly
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inflammatory form of programmed cell death in these cells (Galloway et. al, 2015). On the other
hand, infected cells activate caspase 3 and die from apoptosis (see figure 5).
Figure 5- Caspase-3Dependent Apoptosis and
Caspase-1- Dependent
Pyroptosis in CD4 T cell
Death.
Source: Doitsh, G., &
Greene, W. C. (2016).
Dissecting How CD4 T
Cells Are Lost During
HIV Infection. Cell host
& microbe, 19( 3),
280–291.
doi:10.1016/j.chom.2016.
02.012

B. PROTEIN KINASES (PK)
When HIV uses integrase to incorporate its newly made DSDNA into our DNA, cellular
sensor DNA-dependent protein kinases senses the breaks in DNA. DNA PK mounts response to
bacterial and viral infection (Burma & Chen, 2004). DNA PK localizes very rapidly to DNA
breaks and phosphorylates itself and other damage-responsive proteins, it appears that DNA–PK
serves as both a sensor and a transducer of DNA-damage signals (2004). This too leads to
programmed cell death.
C. CD8 T CELLS
CD8 T cells, like CD4 T cells, are generated in the thymus and express a T-cell receptor
(TCR), a receptor that recognizes antigens on major histocompatibility complexes (MHC), and
are a vital component in cellular immune response (Wissinger, n.d). When a cell is infected with
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HIV, CD8 T cells are recruited to the lymph nodes, recognize the infected cells by a MHC
dependent process, and are able to lyse cells harboring viral infection by the secretion of perforin
and granzymes (Gulzar and Copeland, 2004). These cytotoxic T-lymphocytes (CTL), can also
eliminate virally infected cells through the engagement of death-inducing ligands expressed by
CD8+ T-cells with death receptors on the surface of the infected cell (2004). CD8 T cells also
express perforin, a molecule that causes cell mediated toxicity after antigen specific stimulation.
Figure 6- T cells
during HIV
infection.
Source: Gougeon, M.
Apoptosis as an HIV
strategy to escape
immune attack. Nat
Rev Immunol 3,
392–404 (2003)
doi:10.1038/nri1087

A study done by Hersperger et al (2010) examined perforin expression in HIV infected
individuals. They found that as HIV-specific performance-expression increased, viral load
decreased. The capability for CD8 T cells to express perforin defines a novel correlation of
control of HIV infection (2010). CTLs can also kill infected or malignant cells via cytokines
tumor necrosis factor alpha (TNF-ɑ) and interferon gamma (IFN-𝛄) or by T cell checkpoint
Fas/Fas ligand that can activate a caspase response (Wissinger, n.d).
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4. INFECTION AT THE ORGANISMAL LEVEL
Figure 7- HIV Infection over
years..
Source: Coffin JM, Hughes SH,
Varmus HE, editors.
Retroviruses. Cold Spring
Harbor (NY): Cold Spring
Harbor Laboratory Press; 1997.
Course of Infection with HIV
and SIV. Available from:
https://www.ncbi.nlm.nih.gov/b
ooks/NBK19374/

A. PRIMARY INFECTION
Primary infection is characterized by a burst of viral replication that can be detected in
the blood 3 weeks after infection (Clark et al. 1991; Daar et al. 1991; Tindall and Cooper, 1991).
Some people experience flu-like symptoms during this time.
B. ACUTE INFECTION
Acute infection occurs about 3-6 weeks after infection and is characterized by increasing
HIV RNA and significant decline of CD4 T lymphocytes in the peripheral blood 2-8 after
infection (Gaines et al. 1990). CD4 T cells may rebound a small amount, but will rarely return to
normal levels. This is also the point where a person infected has the highest likelihood of
transmission. The probability of transmission is positively correlated with the viral burden in
blood; every time the viral burden increases by a factor of 10, the risk of transmission increases
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by a factor of 2.5 (Quinn et al. 2000). The risk of transmission is higher in patients with acute,
early infection, than in patients with established infection (Wawer et al. 2005), partially because
of the high viral load (see figure 7) and because of the homogeneity of the viral load that is
clearly capable of causing infection (Cohen et al. 2011). At the organismal level, symptoms
associated with acute HIV-1 infection are often too vague or nonspecific to lead to a diagnosis
unless there is a high degree of suspicion (2011). Symptoms may include fever, malaise,
pharyngitis, headache, diarrhea, maculopapular rashes, and meningoencephalitis (Coffin et al
1997).
C. CLINICAL LATENCY
After initial effects of HIV that are usually unnoticed, there is a long period referred to as
“clinical latency” that lasts many years after primary infection (dependent on treatment). In this
time, HIV is still active but reproduces at a low level, there is also a steady decline of CD4 T
cells. However, people who take ART during this time can keep an undetectable viral load that
has almost no risk of transmission. Symptoms in this period include fatigue, mild weight loss,
generalized lymphadenopathy, thrush, and shingles (Coffin et al 1997).
A healthy person has about 1200 CD4+ T cells/μl. During latency, a patient's CD4 T
cells continue declining. At about 500 CD4 T cells/μl, a patient may experience oral lesions,
thrombocytopenia, basal cell carcinoma of the skin, and Mycobacterium tuberculosis ( Coffin et
al 1997).
D. AIDS
When CD4 T cells fall under 200 cells/μl, the patient has AIDS and is susceptible to
AIDS-defining opportunistic infections and neoplasms (1997). These include: Toxoplasma
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gondii, Cryptosporidium, Treponema Pallidum, Candida albicans, K
 aposi’s sarcoma, aseptic
meningitis, myelopathies, myopathy, and AIDS dementia complex (Coffin et al 1997). HIV
progresses until virtually all CD4 T cells are lost. Viral replication thrives as an outcome. A
patient with AIDS does not die from AIDS itself, but by succumbing to these opportunistic
infections and neoplasms (Coffin et al 1997).
5. DRUG THERAPY FOR HIV
After multiple decades and millions of deaths worldwide, an effective cure for HIV has
not been found. Antiviral combination drug therapy (ART) was a major breakthrough because it
effectively reduced the viral load and preserved immune function, prolonging the survival of
HIV-infected patients. There are 7 main classes of drugs that can halt HIV at different stages in
the HIV life cycle (see Figure 4). These include:
A. CCR5 ANTAGONIST
These drugs are designed to prevent HIV infection of CD4 T-cells by blocking the CCR5
receptor (Rao, 2009). Most patients have chemokine coreceptor CCR5, few have CXCR4. When
the CCR5 receptor is unavailable, ‘R5-tropic’ HIV cannot bind with a CD4 T-cell to infect the
cell (2009). Generic names of this drug include: maraviroc (MVC).
B. POST ATTACHMENT INHIBITORS
This design focuses on decreasing the flexibility of the CD4 receptor, hindering the
access of CD4- bound gp120 to bind with CCR5 or CXCR4 due to its reduced stability (Henrich
and Kuritzkes, 2013). Generic names of this drug include: ibalizumab-uiyk.
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C. FUSION INHIBITORS
These drugs prevent membrane fusion by competitively binding to gp 41 and blocking
the formation of the post fusion structure (Eggink et al, 2010). Generic names of this drug
include: enfuvirtide.
D. INTEGRASE INHIBITORS
This design blocks the insertion of HIV DNA into the host cell’s DNA.integrase is
essential for retroviral replication, and the absence of integrase means that integrase inhibitors do
not interfere with normal cellular processes, and therefore have a high therapeutic outcome
(Pommier et al, 2005). Generic names of this drug include: Dolutegravir, and raltegravir.
E. NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)
These drugs bind directly to reverse transcriptase and inhibit reverse transcription
(Sluis-Cremer et al, 2008). Generic names of this drug include: doravirine, efavirenz, etravirine,
and nevirapine.
F. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)
This design uses DNA analogs to compete with the naturally occurring nucleosides that
enable reverse transcription to prevent their transformation into viral RNA (Fowler et al, 2014).
Generic names of this drug include: abacavir, emtricitabine, lamivudine, tenofovir disoproxil
Fumarate, and zidovudine.
G. PROTEASE INHIBITORS
These drugs block the splicing of the long viral RNA accomplished by pro (Flexner,
1998). Generic names of this drug include: atazanavir, darunavir, fosamprenavir, ritonavir,
saquinavir, and tipranavir.
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H. DRUG THERAPY IN TODAY’S WORLD
These drugs have proven to be very successful, however, they can produce a lot of
toxicity and viral resistance long-term (Von Laer et al, 2006). Long term complications of
HIV-1 have recently been tied to the adverse effects of ART. Each drug class has been tied to its
own side effects. To name a few, “nucleoside/nucleotide reverse transcriptase inhibitors are
associated with lactic acidosis, lipodystrophy, and hyperlipidemia; non-nucleoside reverse
transcriptase inhibitors are associated with neuropsychiatric symptoms, rash, liver toxicity, and
lipid abnormalities; and protease inhibitors are associated with gastrointestinal intolerance and
glucose and lipid abnormalities” (Ruest, 2011).
Aside from the side effects, however, ART has proven to keep CD4 T cell counts within
a normal range and suppress HIV. Currently, there are 11 combination medications in pill form
that only need to be taken once a day to suppress HIV and keep CD4 T cells within the normal
range. Examples of these medications include Atripala, Striblid, Juluca, Symtuza and Dovato.
Even so, taking a pill everyday and being reminded of an HIV diagnosis can take its toll
on just about anyone. In March of 2020, Canadian health officials announced approval of
combination drug Cabenuva, a once a month injection for treatment of HIV-1 infection in adults
whose viral load is suppressed (<50 HIV RNA copies/ mL or taking oral ART for at least 6
months) (Swindells et al, 2020). The drug contains cabotegravir (integrase inhibitor) and
rilpivirine (non-nucleoside reverse transcriptase inhibitor).
In the study conducted by Swindells et al. (2020), patients were randomized to either
continue oral ART or switch to monthly intramuscular injection of what has been trademarked
“Cabenuva”. After 48 weeks of monitoring, results showed <50 HIV RNA copies/mL in 92.5%
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of those taking Cabenuva, and in 95.5% taking oral ART (Swindells et al., 2020). There is little
data on long-term toxicity and long-term side effects. Cabenuva has recently been denied FDA
approval due to manufacturing issues. There is current research on Cabenuva being effective
once every two months.
6. GENOME EDITING & INTRODUCTION TO CRISPR/CAS9
Genome editing was first introduced in 1962 by Szybalska and Szybalski, their study
used the basis that cells require either dihydrofolate reductase (DHFR) or hypoxanthine
phosphoribosyl transferase (HGPRT) to synthesize nucleic acids. Szybalska and Szybalski
(1962) used a human bone marrow cell line D98S that were either HGPRT- or HGPRT+
(DHRFR was inhibited in both), only HGPRT+ cells were able to synthesize DNA. HGPRT+
cell DNA was isolated and transformed into HGPRT- cells in a
hypoxanthine-aminopterin-thymidine (HAT) medium, and the cells did not die. This was the first
documented gene transfer in mammalian cell lines. Waclaw Szybalski is noted as the “Father of
Gene Therapy.”
CRISPR/Cas9 is a gene editing technology that is revolutionizing biomedical research.
Clustered regularly interspaced palindromic repeats (CRISPR) and CRISPR associated protein 9
(Cas9) work hand-in-hand to correct errors in a genome, downregulate genes, and upregulate
genes (Redman et al, 2016).
The mechanism behind CRISPR/Cas 9 happened naturally, as it was a way for bacteria to
protect themselves from infection of viruses. When the bacteria detected viral DNA, it created a
strand of DNA that matched that of the virus (CRISPR), and an endonuclease (Cas9) that cut the
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viral genome when the guide DNA matched its target. This process disabled the virus, and
therefore the bacterium avoided infection.
Researchers found that this breakthrough could be used in any cell type, including human
cells. A CRISPR/Cas9 complex enters the nucleus and locks onto the Protospacer Adjacent
Motif (PAM) which is a couple nucleotides downstream from the cut site and is required by the
CRISPR/Cas9 complex (Importance of the PAM sequence in CRISPR experiments, n.d) (see
figure 8). Once the target DNA is matched with the guide RNA (gRNA), Cas 9 makes the cut.
Repair after the DNA cut may occur via two pathways: non-homologous end joining, typically
leading to a random insertion/deletion of DNA, also known as a double strand break (DSB),
inducing a mutation that will deactivate or “silence” the gene (Redman et al, 2016) (see figure 8).
Figure 8- Mechanism of CRISPR/Cas
9 genome editing.
Source: Ding Y, Li H, Chen L, Xie K,
(2016, May 6). Recent Advances in
Genome Editing Using CRISPR/Cas9.
Retrieved from
https://www.frontiersin.org/articles/10
.3389/fpls.2016.00703/full

Repair can also be done via homology directed repair (HDR) where a homologous piece
of DNA is used as a repair template, this allows a healthy gene to replace the cut out mutant
gene; thus, completing a precise genome modification (2016).
Current in-vitro research is focused largely on infectious diseases like HIV.
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A. CRISPR/CAS 9 AND HIV
It is believed that latent infected immunal cells work as an HIV reservoir and allow for
viral persistence, despite ART (Finzi et. al, 1997). A study done by Hu et al (2014) used HIV-1
gRNAs to stop long terminal repeat (LTR) transcriptional activity (important for HIV gene
regulation) and eradicate proviral DNA from the latent myeloid cells in the brain that serve as an
HIV reservoir.
The target gene was the HIV-1 LTR promoter U3 region. The U3 region contains the
TATA box and several upstream transcription factor binding sites (TFBS) that control
transcription (Opijen et al, 2004). Four gRNAs were synthesized (LTRs A-D). DNA
oligonucleotides complementary to gRNAs A-D were placed into a “humanized Cas9 expression
vector” (2014). Microglial cell line CHME5 was used, which contained a single, round, HIV-1
vector that also contained an enhanced green fluorescent protein (EGFP).
Histone deacetylases (HDAC) are natural occuring enzymes that remove the acetyl
groups on a histone, allowing the histones to tightly wrap around the DNA, and therefore have a
repressive influence on transcription (Haberland et al, 2009); the CHME5 cells were treated with
trichostatin A (TSA), an HDAC inhibitor, reactivating transcription of the integrated provirus
and expression of EGFP and HIV proteome (Hu et al, 2014).
Expressing the gRNAs plus Cas9 decreased the fraction of TSA-induced EGFP-positive
CHME5 cells and caused a 190 bp deletion fragment between A and B target sites (Hu et al,
2014) (see figure 9).
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Figure 9- Reduction in TSA-induced
EGFP-positive CHME5 cells after introduction
of gRNAs and Cas9.
Source: Hu, W., Kaminski, R., Yang, F., Zhang,
Y., Cosentino, L., Li, F., … Khalili, K. (2014).
RNA-directed gene editing specifically
eradicates latent and prevents new HIV-1
infection. Proceedings of the National Academy
of Sciences of the United States of
America, 111(31), 11461–11466.

Furthermore, parent promonocytic cell line U-937 was infected with HIV-1 and derived
subclone U1, which serves as an HIV-1 latency model for infected immune cells, exhibiting
low-level constitutive viral gene expression that can be upregulated (Folks, et al 1987). U1 cells
express the provirus in chromosome X (contains 9,709 proviral HIV bp and 226 flanking bp) and
chromosome 2 (contains 9,709 proviral HIV bp and 467 flanking bp). In U1 cells that expressed
LTR- A/B gRNAs and Cas9 there were 2 segments in chromosome x (only 833 bp and 670 bp)
(see figure 10) and one segment in chromosome 2 (1,102 bp).

Figure 10- Cutting out HIV genome from U1 Xp11.4 chromosome.

Human Immunodeficiency Virus: A Literary Review on Gene Editing, Cytotherapy, and Medicinal Marijuana as Therapies for HIV.

21
Source: Hu, W., Kaminski, R., Yang, F., Zhang, Y., Cosentino, L., Li, F., … Khalili, K. (2014). RNA-directed gene editing specifically eradicates
latent and prevents new HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 111(31),
11461–11466.

The study concluded that gRNAs A/B enabled Cas9 to cut out the HIV 5’-3’ LTR
spanning viral genome segment in both chromosomes. The results of this study minimized
toxicity while efficiently abolishing integrated HIV-1 provirus.
A recent experiment, done by Yu et al, 2018, simultaneously “knocked out” the CXCR4
and CCR5 genes in CD4+ T cells via CRISPR/Cas 9. As stated previously, chemokine
coreceptors CCR5 and CXCR4 bind with either R5 tropic or X4 tropic HIV-1, respectively.
There is a class of drugs that works as a CCR5 antagonist (see drug therapy section). However,
these drugs create toxicity and therefore cause risk when a latent infection has affected the brain
and other major neurological regions. There became a need to eradicate both co receptors on
cells that are post infection. In their results, the efficiency of gene modification was 55% for
CCR5 and 36% for CXCR4 CD4+ T cells (Yu et. al, 2018).
Furthermore, 9% of modified GHOST CXCR4+CCR5+ (cells with both co receptors)
cells had disruptions in the CXCR4 and CCR5 loci (Hu et al, 2018). The results demonstrate the
safety and efficiency of gene modification technology as a functional cure for infectious diseases
like HIV-1.
B. siRNA AND HIV
Small interfering RNA (siRNA), a 21–23 nucleotide DSRNA responsible for
post-transcriptional gene silencing, has attracted great interests as promising genomic drugs, due
to its strong ability to silence target genes in a sequence-specific manner (Ku et al, 2016). In
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1998, Fire et al. discovered that short DSRNA specifically regulates gene expression. A notable
study done by Song et al (2005), designed a protamine-antibody fusion protein (F105-P) to
deliver siRNA to HIV-1-infected or envelope transfected cells. In efforts to reduce viral
replication via a dose dependent manner, they loaded the F105-P with gag siRNA. The results
show that the proportion of productively infected cells declined from 85% to 36% when 1 nM of
gag siRNA was added. Even with a ten-fold less siRNA, only 45% of cells were staining for
HIV-1 gag (see figure 11).

Figure 11- Treating HIV-1 infected cells with gag siRNA.
Source: Song, E., Zhu, P., Lee, S. et al. Antibody mediated i n vivo delivery of small interfering RNAs via cell-surface receptors.Nat Biotechnol
23, 709–717 (2005). https://doi.org/10.1038/nbt1101

C. APTAMERS + siRNA AND HIV
Nucleic acid aptamers are oligonucleotides that function similar to antibodies by binding
to a specific target molecule. Riboswitches are an example of naturally-occuring aptamers. RNA
aptamers can be designed to target specific cell receptors while carrying and delivering siRNA.
A study done by Zhou et al, 2009, synthesized covalent aptamer-siRNA chimeras (Ch A-1/ Ch
B-68) to bind to gp120 and send siRNA to target tat/rev.
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They also synthesized aptamers without siRNA (A1/B68) for the same task. Both
aptamers and complexes were inserted in HIV-1 infected T lymphoblast cell derivative CEM T
cells and primary blood mononuclear cells (PBMCs) and incubated over 9 days. A p24 antigen
analysis was done on day 3,5,7 and 9 to determine if the aptamer and aptamer/chimera complex
affected HIV-1 transcription. Results showed that all aptamer and aptamer/chimera complexes
inhibited p24 production with the greatest inhibition done by aptamer/chimera complex A1 (see
figure 12). Both studies demonstrate the effectiveness of siRNA inhibiting HIV propagation.
Figure 12- HIV-1 inhibition by gp120 aptamer and
gp120-aptamer-chimera-complex.
Source: Zhou, J., Swiderski, P., Li, H., Zhang, J., Neff,
C. P., Akkina, R., & Rossi, J. J. (2009). Selection,
characterization and application of new RNA HIV gp
120 aptamers for facile delivery of Dicer substrate
siRNAs into HIV infected cells. Nucleic acids
research, 37( 9), 3094–3109. doi:10.1093/nar/gkp185

D. siRNA AGAINST HIV REVERSE TRANSCRIPTASE
Reverse transcriptase (RT) is a primary target for antiviral therapies and drugs. In a study
done by Surabhi and Gaynor (2002) two siRNA’s were designed to target the HIV-1 RT gene
(RT1 and RT2) and tested its efficacy in replication inhibition in MAGI cells (HeLa stem cell
line derivative).
The MAGI cells were subjected to either RT1, RT2, tax siRNA (a control group for the
study, human T-cell leukemia type 1 siRNA), and oligofectamine (a transfection reagent used to
properly transfect eukaryotic cells with oligonucleotides and siRNA). After 6 days, the cultures
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were assayed for the p24 antigen levels. Transfection of either RT1 or RT2 siRNA inhibited
HIV-1 replication in MAGI cells by >90% compared to tax siRNA or oligofectamine alone
(Surabhi and Gaynor, 2002).
Figure 13- Assay of p24 antigen in MAGI cells
transfected with RT 1, RT2, Tax (control), and OF
(control)
Source: Surabhi, R. M., & Gaynor, R. B. (2002). RNA
interference directed against viral and cellular targets
inhibits human immunodeficiency Virus Type 1
replication. Journal of virology, 76(24), 12963–12973.
https://doi.org/10.1128/jvi.76.24.12963-12973.2002

E. GENOME EDITING IN TODAY'S WORLD
CRISPR/CAS 9 differs from RNAi (siRNA/ shRNA) because CRISPR/CAS 9 has the
ability to generate substitute genes (knock-in), fix a gene, and integrate a gene at a specific locusnot discussed since HIV-1 requires a “knock-out.” There are far less concerns about RNAi than
about CRISPR/ CAS 9.
CRISPR/ CAS 9 has proven to be a revolutionary tool in biomedical research and has
extreme potential in gene editing therapies. Previous explorations of CRISPR/CAS 9 were
mainly conducted in vitro or in animal germlines, the translatability is limited to: tissues with
adult stem cells susceptible to culture and manipulation or currently impermissible due to ethical
concerns (Dai et al., 2016). Recently, three studies (Tabebordbar, et al., 2016; Nelson, et al.,
2016; Long, et al., 2016) delivered CRISPR/ CAS 9 through intramuscular, intraperitoneal or
intravenous injection to correct a nonsense mutation in the dystrophin gene that leads to
Duchenne Muscular Dystrophy (DMD) in mouse models, resulting in restoration of dystrophin
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expression and muscle function. CRISPR/ CAS 9 HDR was also delivered through intravenous
injection to mice with human liver disease (Yang et al., 2016; Yin et al., 2016).
The viral vectors used are adeno-associated viruses (AAVs) which is a non-pathogenic
SSDNA virus that can insert site-specific genetic material on chromosome 19 with very high
certainty. Chromosome 19 has the highest gene density of all human chromosomes (Grimwood
et al, 2004). In 2019, the FDA approved clinical trials on patient volunteers in three areas;
cancers, blood disorders, and eye disease; all of which mean no genetic change can be passed
onto offspring.
There are many challenges to CRISPR/ CAS 9 in-vivo. Specificity of CRISPR/CAS 9 can
cause off-target side effects, which may lead to uncontrollable consequences such as malignant
transformation (Dai et al., 2016). This challenge can be reduced by modifying Cas9 to a high
fidelity (Kleinstiver et al, 2016), or optimizing the sgRNA (Doench et al., 2016). Other
challenges include (1) AAVs themselves have a small genome and therefore have a limited cargo
capacity (2) HDR-mediated repair can require patient-specific design of sgRNAs and donor
templates, which can challenge the mass-production and cost of this therapy (Dai et al., 2016).
Some challenges to CRISPR/Cas9 are also challenges to RNAi such as (3) translatability
to in-vivo delivery (4) immunogenicity and (5) fitness of edited cells.
In 2018, FDA approved Onpattro (patisiran), an RNAi drug used for the treatment of
peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated
amyloidosis (HATTR) which causes buildup of abnormal amyloid protein in peripheral nerves
and is often fatal (FDA, 2018). Onpattro has siRNA that targets the abnormal protein
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transthyretin (TTR) which reduces the accumulation of amyloid deposits (2018). An annual
course of this drug costs $450,000, making affordability and access a major issue.
Perhaps the biggest challenge to CRISPR/CAS 9 genome editing is not physical, but
ethical. In 2018, Chinese doctor Jian Kui He claimed to have created the first gene-edited babies,
designed to be naturally immune to HIV-1 by disabling the CCR5 gene via CRISPR/CAS 9 (Li
et al., 2019). This created an uproar worldwide, especially because other effective, cheap and
more accessible treatments are available to prevent transmission of HIV-1. China explicitly
banned clinical procedures of gene-editing on human embryos for reproductive purposes (2019).
Hu was sentenced to three years in prison for illegal practices.
Many people struggle with the concept of gene editing and believe that genome editing
for therapeutic purposes will then begin use for non-therapeutic uses and “enhancements.”
Furthermore, gene editing on germ-line cells has been a topic of much debate, since in-vitro
fertilization (IVF) and preimplantation genetic diagnosis (PGD) is available (What are the ethical
concerns of genome editing, 2017). Although there is an all-too-real threat of “designer babies,”
IVF and PGD simply may not be enough for parents who are homozygous for a disease-causing
variant.
Other concerns unique to CRISPR/CAS 9 include (1) future generations that have been
affected by the germline editing did not provide consent (2) future effects on the germline are
unknown (3) the technology will be available only to the wealthy, creating a society defined by
the quality of their altered genome (2017).
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7. CYTOTHERAPY INTRODUCTION
Cytotherapy, or cell therapy, is the transplantation of cells to replace damaged tissue
and/or cells (Facts about cellular therapies, n.d). The first successful blood transfusion occured in
1818 by James Blundell, MD to a patient that was hemorrhaging during childbirth. In 1931, Paul
Niehans, MD injected bull parathyroid gland cells into a patient suffering from seizures. Both
occurrences yielded successful results. Furthermore, research suggests the field has tremendous
potential to treat a plethora of diseases.
A. STEM CELLS AND HIV
Stem cells are precursors to all cell types. They are undifferentiated and can form many
cell types including some nerve and cardiac cells. Hematopoietic stem cell (HSCs)
transplantation, or bone marrow transplantation (BMT), is the most common cell therapy and is
used to treat many blood conditions like leukemia and sickle cell anemia (Facts about cellular
therapies, n.d). HSCs are capable of forming red blood cells, platelets, and white blood cells
(immune system cells) (see figure 14).
Figure 14- Hematopoietic stem
cell differentiation.
Source: © 2001 Terese
Winslow (assisted by Lydia
Kibiuk)

In 1956, the first successful bone marrow transplant was performed by E. D. Thomas,
MD. The donated HSCs replaced the hematopoietic system of the recipient over time. It's also
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important to note that human leukocyte antigen (HLA) matching is necessary for blood and bone
marrow transplants. HLAs are membrane surface markers that the immune system uses to
recognize foreign cells. The higher the HLA match between donor and recipient, the likelier the
transplant will be successful.
A single HSC is capable of reestablishing the entire blood forming system of an
irradiated mouse (Karp et al, 2018). Furthermore, saving the umbilical cord blood of a newborn
baby provides a source of HSCs if they are needed later (2018). Stem cells can also be collected
from peripheral blood (PB) using a harvesting machine.
The first person has been cured of HIV-1 via bone marrow transplant. Homozygosity for
a 32 base pair deletion in the CCR5 (CCR5 delta 32) allele results in an inactive CCR5 gene,
defects in HIV-1 coreceptor leads to resistance of HIV-1 infection (Liu et al., 1996). In a study
by Hütter et al., (2009) stem cells were transplanted from a donor who was homozygous for
CCR5 delta 32 (CCR5 delta32/delta32) deletion into a patient with both acute myeloid leukemia
(AML) and HIV-1 infection.
After stem cell transplantation (SCT) there was no viral rebound and the patient
discontinued ART (see figure 15). CCR5 delta 32 deletion is observed in approximately 1% of
the white population, and offers a natural resistance to HIV-1 infection (Hütter et al., 2009). It is
important to note this method would not be successful with CXCR4 tropism. Essentially, blood
cells were replenished with healthy cells, the immune system was “replaced” as his resulting T
cells were immune to HIV invasion.
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Figure 15- Treatment course of AML
and HIV-1 via PCR after SCT.
Source: Hütter, G., Nowak, D.,
Mossner, M., Ganepola, S., Müßig,
A., Allers, K., ... & Blau, I. W. (2009).
Long-term control of HIV by CCR5
Delta32/Delta32 stem-cell
transplantation. New England Journal
of Medicine, 360( 7), 692-698.

B. CAR STEM CELLS AND HIV
The primary purpose of a chimeric antigen receptor (CAR) is to direct a T cell to
specifically target an antigen of interest (Zhen et al., 2017). A study done by Kitchen et al,
(2009) genetically programmed a chimeric antigen receptor (CAR) in HSCs that successfully
turned into mature CD8+ cytotoxic T lymphocytes that expressed an anti-HIV T cell receptor
(TCR). The transduction directed the maturation of a large quantity of polyfunctional, HIV
specific CD8+ cells capable of recognizing and killing HIV cells in mice (2009). The result was
a significant % of HIV cell lysis (see figure 16).
Figure 16- Lytic activity of modified HSCs.
Source: Kitchen, S. G., Bennett, M., Galić, Z., Kim, J., Xu, Q.,
Young, A., Lieberman, A., Joseph, A., Goldstein, H., Ng, H.,
Yang, O., & Zack, J. A. (2009). Engineering antigen-specific T
cells from genetically modified human hematopoietic stem cells
in immunodeficient mice. PloS one, 4(12), e8208.
https://doi.org/10.1371/journal.pone.0008208
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C. HUMAN EMBRYONIC STEM CELLS (hESCs)
Human embryonic stem cells differ in that they are nonautologous and require an embryo
donor. HESCs are isolated from blastocysts and are pluripotent, which give rise to all somatic
cell types in the embryo (Vazin and Freed, 2010). The farther a cell is in development, the less
pluripotent it is. HESCs have been isolated from embryos via IVF.
A small tissue is taken from the patient, one somatic cell is fused with donor enucleated
oocyte. The resulting oocyte that has the patient's nucleus develops into an early embryo, and ES
cells are harvested and grown in culture. ES cells are induced to differentiate into the required
cells, which get transplanted into the patient (see figure 17).
HESCs are induced with specific mediums depending on the needed cell type. Generation
of transplantable motor neurons occurs with addition of retinoic acid in the medium (Li et al.,
2005).
Figure 17- Mechanism to obtain differentiated
hESC.
Source: Karp, G., Iwasa, J., & Marshall, W.
(2018, May 10). Karp's Cell Biology, 8th
Edition, Global Edition. Retrieved from
https://www.wiley.com/en-cw/Karp's Cell
Biology, 8th Edition, Global
Edition-p-9781119456292

After the study done by Hütter et al., (2009), a search for an unlimited source of CCR5
delta 32 deletion cells began. In a study done by Pomerantseva et. al, (2011), 137 hESC lines
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were tested (from the Reproductive Genetics Institute’s hESC lines collection), and found 12
hESC lines with CCR5 delta 32 deletions, 11 heterozygous and 1 homozygous (see figure 18).
Figure 18- gel electrophoresis testing for CCR5 delta 32
deletion
Source: Pomerantseva, E., Kukharenko, V., Goodman, A.,
Vrlinsky, O., Rechitsky, S., & Kuliev, A. (2011). Human
embryonic stem cell lines with CCR5-del32 allele conferring
resistance to HIV. Stem Cell Discov, 1, 67-70.

The possibility of unlimited quantities of these cells will overcome many obstacles. First
and foremost the need for a bone marrow transplant will be eradicated, which is a painful, long
procedure that may cause later complications. Also, a study by Taylor et al. (2005) emphasized
that only 10 highly selective donors could provide the maximum practical benefit for HLA
matching. Therefore, HIV-1+ patients that do not have blood cancers may be eligible for said
treatment.
D. INDUCED PLURIPOTENT STEM CELLS (iPSCs)
Induced pluripotent stem cells (iPSCs) are similar to hESC but do not require the use of
an embryo. The discovery of iPSCs revolutionized what was thought about cell differentiation. It
was believed that cell differentiation was irreversible, once a liver cell became a liver cell, it
could never turn into any other cell. A study done by Yamanaka and Takahashi (2006)
reprogrammed a mouse connective tissue fibroblast into a pluripotent stem cell by introducing 4
genes novel to embryonic stem cells (Oct3/4, Sox2, c-Myc, and Klf4). The study proved
pluripotent stem cells could be generated from a fully differentiated cell, and completely
revolutionized biomedical research. IPSc have been used to correct sickle cell anemia in mice.
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A study done by Higaki et al. (2018) used iPSCs transduced with short-hand pin RNA
(shRNA) lentivector to target the HIV-1 promoter region (shPromA) to halt HIV-1 replication.
The treated iPSCs successfully differentiated into macrophages. As mentioned in the gene
therapy section, RNAi uses a sequence specific guide. In order to confirm that the transcriptional
suppression was sequence specific and not off-target silencing, the scientists created shPromA
and shPromA-M2, that has a two nucleotide mismatch from shPromA (Higaki et al., 2018). The
iPSC-derived macrophages were subjected to CCR5-tropic HIV-1 infection (2018).
Transcriptional activity was measured at day 4 and day 11, iPSC-derived macrophages
transfected with shPromA inhibit HIV-1 infection, 10 time reduction at day 4 and 20 time
reduction by day 11 (see figure 19). Similarly, reverse transcriptase activity was measured and
similar results were established.
Figure 19- reduction in HIV replication in iPSC- derived
macrophages expressing shPromA, shPromA-M2, and control
(WT).
Source: Higaki, K., Hirao, M., Kawana-Tachikawa, A., Iriguchi,
S., Kumagai, A., Ueda, N., Bo, W., Kamibayashi, S., Watanabe,
A., Nakauchi, H., Suzuki, K., & Kaneko, S. (2018). Generation
of HIV-Resistant Macrophages from IPSCs by Using
Transcriptional Gene Silencing and Promoter-Targeted RNA.
Molecular therapy. Nucleic acids, 12, 793–804. Htt
ps://doi.org/10.1016/j.omtn.2018.07.017

In a study done by Kambal et al (2010), human hematopoietic stem cells (HSCs) were
generated into anti HIV-1 iPSCs (containing lenti viral CCR5 shRNA and human/rhesus
chimeric TRIMɑ gene) that differentiated into HIV-1 resistant immune cells. The TRIMɑ gene
was generated by replacing stretch of 11 human amino acids with 13 amino acids from the rhesus
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macaque essential for HIV-1 restriction (Kambal et al., 2010). The derived anti-HIV
macrophages, wild type (control) peptide (WT), and enhanced green fluorescent protein (EGFP)
were cultured with CCR5 tropic HIV-1 and assayed for p24 antigen postinfection.
Results show that at post-infection day 15, there was a over a 2-log reduction in p24
antigen in the anti-HIV macrophages than the WT and EGFP cultures (Kambal et al., 2010) (see
figure 20). By generating a sufficient quantity of iPSCs expressing the anti-HIV genes, the cells
can replace the immune system with HIV- resistant immune cells.
Figure 20- reduction in HIV replication in iPSC- derived macrophages
expressing anti-HIV genes.
Source:Kambal, A., Mitchell, G., Cary, W., Gruenloh, W., Jung, Y.,
Kalomoiris, S., Nacey, C., McGee, J., Lindsey, M., Fury, B., Bauer, G.,
Nolta, J. A., & Anderson, J. S. (2011). Generation of HIV-1 resistant and
functional macrophages from hematopoietic stem cell-derived induced
pluripotent stem cells. Molecular therapy : the journal of the American
Society of Gene Therapy, 19( 3), 584–593.
https://doi.org/10.1038/mt.2010.269

E. iPSC-NKs, hESC-NKs, PB-NKs, UCB-NKs AND HIV
Natural killer cells are vital in controlling HIV-1 propagation. NK cells are part of the
innate immune system, meaning they do not require previous exposure to an antigen, and instead
recognize antigens on MHCs. NK cells, B lymphocytes, and T lymphocytes (all WBC) are
differentiated from lymphoblasts. In a study done by Ni et al. (2011), hESCs, peripheral blood
(PB) cells, umbilical cord blood cells (UBC), and iPSCs were differentiated into NK cells and
successfully suppressed HIV replication. The stem cells successfully differentiated into NK cells,
as tested by cell surface markers and cytolytic activity against tumor cells. CEM-GFP T cell line
was infected with HIV-1 NL4-3 and then cultured with each stem cell population (Ni et al.,
2011). Quantification of p24 gag protein in the untreated cultures and treated co cultures show
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the reduction in HIV-1 activity via stem cell differentiation (see figure 21) at different
effector-to-target cell (E:T) ratios.
Figure 21- reduction in HIV replication in stem cell co cultures. (E) Red: no
treatment; 1:1 ET- UCB-NK cells: maroon, hESC-NK cells: blue; 10:1 ETUCB-NK cells: dark green, hESC-NK cells: lilac.
(F) Red: no treatment; 1:1 ET- iPSC-NK cells: dark blue, PB-NK cells: light
green; 5:1 ET- iPSC-NK cells: orange, PB-NK cells: purple.
Source:Ni, Z., Knorr, D. A., Clouser, C. L., Hexum, M. K., Southern, P.,
Mansky, L. M., Park, I. H., & Kaufman, D. S. (2011). Human pluripotent
stem cells produce natural killer cells that mediate anti-HIV-1 activity by
utilizing diverse cellular mechanisms. Journal of virology, 85( 1), 43–50.
https://doi.org/10.1128/JVI.01774-10

In the same study, co-NK cells (hESC-NK, UBC-NK, iPSC-NK, PB-NK) were incubated
with HIV-1 infected CD4+ T cells, and levels of CD107a and CD56 expression were measured
(proteins that are expressed during NK cytolytic activity) (Ni et al., 2011). At day 7 to 10 of
HIV-1 infection, CD levels were assayed. The results show a significantly higher percentage of
CD activity in cultures with co-NK cells and HIV-1 infected CD4+ T cells versus co-NK cells
with noninfected CD4+ T cells (see figure 22). All co-NK cells provided cytolytic activity
against HIV-1 infected CD4+ T cells.
Figure 22- co-NK cell cytolytic activity against HIV-1 infected
CD4+ T cells
Source:Ni, Z., Knorr, D. A., Clouser, C. L., Hexum, M. K.,
Southern, P., Mansky, L. M., Park, I. H., & Kaufman, D. S.
(2011). Human pluripotent stem cells produce natural killer
cells that mediate anti-HIV-1 activity by utilizing diverse
cellular mechanisms. Journal of virology, 85( 1), 43–50.
https://doi.org/10.1128/JVI.01774-10
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F. CYTOTHERAPY IN TODAY’S WORLD
Today, stem cells that come from bone marrow or in blood transplant are used in
transplant procedures to treat patients with cancers and disorders of the blood and immune
system (FDA Warns About Stem Cell Therapies, n.d). The only stem cell based products that are
FDA-approved in the US are hematopoietic progenitor cells derived from cord blood (FDA
warns about Stem Cell Therapies, n.d). Examples of diseases treatable with FDA approved stem
cell procedures include, but are not limited to: leukemias, lymphomas inherited RBC or platelet
abnormalities, neutropenias, phagocyte disorders, lysosomal storage disorders, and
myeloproliferative disorders (Stem cell Treatments and Products Approved by the FDA, 2019).
A bone marrow transplant costs an average of $193,000 per patient (Westerman and Bennett,
1996). Despite FDA regulations, clinics have begun using autologous stem cell therapies to treat
knee pain and arthritis.
There are many concerns regarding stem cells, including the failure of cells to work as
expected. In other words, the cell may have acquired a few characteristics of the new cell type
but not any new function (Catacchio, 2013). Mesenchymal stem cells from adipose tissue (MSC)
derived neurons exhibited synaptic transmission, but no evidence proved that activity was
modulated by neurotransmitters (Cho et al., 2005). Hence, it is critical to prove required cellular
activity by means of experimentation in in-vivo-like environments.
Perhaps the largest concerns of stem cell therapy are hematological (including AML and
chronic myeloid leukemia) and non-hematological (teratoma and non-teratoma tumors)
(Anisimov et al., 2010).
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Hematological malignancies can occur due to donor stem cells undergoing blast
transformation under certain factors in the recipient, thus causing de novo malignancies (2010).
A study done by Thomas et al., 1972 witnessed leukaemic transformation of engrafted human
marrow cells in-vivo. Another mechanism that can lead to post-transplantation hematological
malignancies is donor stem cells may have already transformed before the moment of
transplantation (Anisimov et al., 2010). It was demonstrated by Glasser et al., (2010) both the
recipient and donor synchronously developed AML after bone marrow transplant. This can be
due in part to a genetic predisposition of stem cells to blast transformation (Anisimov et al.,
2010).
Non-hematological malignancies can also occur after stem cell transplantation. The likely
mechanism is PB stem cells and bone marrow stem cell material can be contaminated with
metastatic donor cells able to cause tumors in recipients. There have been several cases of
Kaposi sarcoma development in stem cell recipients (Avital et al., 2007; Helg et al., 1994;
Palencia et al., 2003).
In order to prevent malignancies, prolonged differentiation (culturing cells for a
prolonged period of time versus short period of time pre-implantation) may be key (Anisimov et
al., 2010). A matter of a few more days in-vitro can decrease the proliferation potential and
pluripotency of the cells and, therefore, the risk of teratoma/ tumor growth (Anisimov et al.,
2010).
Another mechanism that may be vital in preventing malignancies is the introduction of
suicide genes, that will activate apoptosis if the grafted cells become tumorigenic (Anisimov et
al., 2010). A study done done by Schuldiner et al. (2003), transduced herpes-simplex-virus
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thymidine kinase (HSV-TK) in hESCs prior to implantation, and tumor growth was stopped and
eliminated after treatment of FDA approved ganciclovir (induces destruction of HSV-TK+ cells
and is non lethal to other cell types).
There is a large ethical concern for the use of hESCs. A doctor at the Harvard Stem Cell
Institute emphasized that opponents argue the research is unethical, because deriving the stem
cell destroys the blastocyst, an unimplanted human embryo at day 6-8 of development
(Examining the ethics of embryonic stem cell research, n.d). He also stated however, it is
important to note that the embryo is not implanted and growing in a woman’s uterus, it is a
blastocyst, a cluster of 180-200 cells growing in a petri dish (Examining the ethics of embryonic
stem cell research, n.d).
Lastly, there is also concern of a residual memory in iPSCs. In a study done by Kim et al.
(2010), iPSCs harbored residual DNA methylation signatures characteristic of their somatic
tissue of origin. This “epigenetic memory” is favorable if the differentiation is along lineages
related to the donor cell, but unfavorable if the differential is a completely different cell type
(Kim et al., 2010). This memory can be reset however, with chromatin modifying drugs.
8. INTRODUCTION ON MEDICINAL MARIJUANA
Cannabis was first cultured approximately in the third millennium B.C in central and
south Asia (Marijuana History, 2019). In its early days, cannabis was used to: treat sore eyes
(China), anesthetize (India), and treat earaches (Greece). Cannabis was brought to the US in the
early 1600’s when Jamestown settlers brought the marijuana plant from Europe (Marijuana
History, 2019).
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There are approximately 100 cannabinoids in the cannabis plant, including
tetrahydrocannabinol (THC), which is thought to be the main psychoactive component (Abrams
and Guzman, 2015). It was found that cannabinoids have a receptor-mediated mechanism; in
1988 the first cannabinoid receptor (CB1) was identified in the brain by attaching a radio-label to
synthetic cannabis (Abrams and Guzman, 2015). The protein is present in essentially all tissues.
What binded to this protein channel remained a mystery until 1992, when the first
endocannabinoid, anandamide, was discovered. Thus confirming the body’s endocannabinoid
system. Endocannabinoids function as neuromodulators, the ligands are in the presynaptic nerve
terminals, binding the endocannabinoid to CB1 activates the G protein, which opens potassium
channels (decrease cell firing), and opens calcium channels (decrease neurotransmitter release)
(Abrams and Guzman, 2015) (see figure 23).
Figure 23- G protein coupling with
Cannabinoid receptor
Source: Abrams, D. I., & Guzman, M.
(2015). Cannabis in cancer care.
Clinical Pharmacology &
Therapeutics, 97( 6), 575-586.

The biological functions “relax, eat, sleep, protect and forget” summarizes the various
functions of the endocannabinoid system (Temple, 2016). In 1993, CB2 was discovered outside
of the brain, with the highest abundance of receptors on the B lymphocytes and NK cells,
suggesting a role in immunity (Abrams and Guzman, 2015).
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A. MEDICINAL MARIJUANA AND HIV
HIV-1 attacks the immune system and begins a life-long battle with the host’s body. A
person with HIV (and ultimately AIDS) can experience AIDs wasting syndrome, nerve damage
(pain to the touch), fatigue and nausea (usually related to medication), depression and anxiety.
Marijuana, some patients say, erases all of these problems and then some (Joy and Mack, 2000).
ART drugs can make the lives of people with HIV miserable. ART drugs (especially
protease inhibitors) are known to make people very sick, nausea, diarrhea, loss of appetite,
vomiting, and more become a way of life for some- very similar to that experienced by cancer
patients during chemotherapy (Joy and Mack, 2000).
The CDC defines AIDS wasting syndrome as the involuntary weight loss of more than
10% of one’s weight, accompanied by diarrhea or fever that lasts more than 30 days. For people
with HIV-1, loss of 5% of their body weight appears life-threatening (Joy and Mack, 2000).
Wasting occurs by two processes, cachexia and starvation. Cachexia results from
disproportionate loss of lean tissue mass; Starvation results from food and/or nutrient
deprivation. Starvation in people with HIV-1 is usually seen from a loss of appetite due to ART
drugs, opportunistic infections that result in ulcers in the mouth, throat and esophagus that make
eating difficult, opportunistic infections that result in extreme diarrhea, and/or the overgrowth of
microbes that naturally live in the digestive tract (Joy and Mack, 2000).
A double-blind study done by Beal et al. (1995), randomized 139 patients
experienciencing AIDS related anorexia to either receive 2.5mg dronabinol (synthetic THC
cannabinoid) twice a day or the placebo. Dronabinol was associated with increased appetite in
just 2-4 weeks of treatment, and the differences between drug and placebo were significant after
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4 weeks of treatment (Beal et al., 1995) (see figure 24). Improvement in mood and decreased
nausea was also significant in patients who received dronabinol. Since increased appetite was
noted about 2-4 weeks after treatment (6 week study), there was limited time to analyze weight
gain/loss of either part, however, weight results still diverged between dronabinol and placebo
treated patients (Beal et al., 1995) (see figure 25). After this study, the FDA approved
dronabinol, under the trademark Marinol, as a treatment for anorexia in patients with AIDS.
Figure 24- Mean appetite change in dronabinol and
placebo patients.
Source: Beal, J. E., Olson, R., Laubenstein, L.,
Morales, J. O., Bellman, P., Yangco, B., ... & Shepard,
K. V. (1995). Dronabinol as a treatment for anorexia
associated with weight loss in patients with AIDS.
Journal of pain and symptom management, 10( 2),
89-97.

Figure 25- Mean weight change in dronabinol and placebo

.

patients

Source: Beal, J. E., Olson, R., Laubenstein, L.,
Morales, J. O., Bellman, P., Yangco, B., ... & Shepard,
K. V. (1995). Dronabinol as a treatment for anorexia
associated with weight loss in patients with AIDS.
Journal of pain and symptom management, 10( 2),
89-97.

In another study done by Foltin et al. (1988) 6 volunteers were randomized to smoke
either 2 cigarettes with THC or a placebo daily (13 days total). All behaviors including food
intake and social activities were recorded since the volunteers were living in a residential
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laboratory. Smoking active THC increased daily caloric intake by 40%, due to increased number
of snack food consumption such as candy bars and potato chips (Fotlin et al., 1988). Today, the
consumption of snack foods after THC intake is referred to as the “munchies.”
It is blatant that medications are needed to prevent tissue loss that occurs from AIDS
wasting syndrome. Current studies are being done using anabolic compounds such as
testosterone and/or growth hormone to increase lean tissue body mass (Joy and Mack, 2000).
Marijuanna does not treat cachexia, however, it has been proven useful in increasing appetite and
weight, as well as decreasing nausea in patients who are using ART drugs.
Peripheral neuropathy (weakness/numbness and pain from nerve damage) affects 10-30%
of patients with AIDS, with the most complaints of pain in the feet/soles (Cornblath and
McArthur, 1988). Sensory neuropathy in HIV cause appears to be a distal axonal degeneration of
sensory neurons with late manifestation of HIV infection (Cornblath and McArthur, 1988).
While some AIDS patients report that neuropathic pain can be relieved by marijuana
consumption, no clinical studies have confirmed the claims (Joy and Mack, 2000).
Furthermore, HIV-1 has a tremendous effect on mood. For many people, anxiety and
depression are common after an HIV diagnosis. Although it is near impossible to distinguish the
treatment of anxiety or depression and the pursuit of a “high,” many patients who began using
marijuana to relieve physical symptoms appreciate the psychological “lift” it provides (Joy and
Mack, 2000).
B. MEDICINAL MARIJUANA TODAY
In the USA today, there are 33 states (and DC) that have legalized medicinal marijuanna
use. In Florida, an individual can register for a medicinal marijuana card if a doctor certifies that
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the individual suffers from one or more of the following: Cancer, Epilepsy, Glaucoma,
HIV/AIDS, Crohn’s disease, Parkinson’s disease, Multiple sclerosis (MS), Medical conditions of
the same kind or class as or comparable to those above, Post-traumatic stress disorder (PTSD),
Amyotrophic lateral sclerosis (ALS), A terminal condition diagnosed by a physician other than
the qualified physician issuing the physician certification, and/or a chronic nonmalignant pain
caused by a qualifying medical condition or that originates from a qualifying medical condition
and persists beyond the usual course of that qualifying medical condition (Marijuana Policy
Project, n.d).
It's important to note that everyone responds differently when using marijuana. Where
some people feel calm, happy, even euphoric, some feel an increase in anxiety, dizziness, and
disconnection from reality (Joy and Mack, 2000). This is why it is important to know which
cannabinoids at which ratio are best suitable for the individual. The two most known
cannabinoids are THC and cannabidiol (CBD).
CBD is used by patients who do not want to experience the psychoactive symptoms of
THC. Different strains of marijuana have different amounts of CBD and THC. It is extremely
important to use what works best for the individual.
C. INTERVIEW
Aside from scholarly studies, peer-reviewed journals, textbooks, etc. It’s extremely
important to hear the efficacy of therapies from those who have experienced them. In this
interview, I converse with Jim Pickett, Senior Director of Prevention Advocacy at the AIDS
Foundation Chicago.
1. How long ago were you diagnosed with HIV?
I was diagnosed in 1995.
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2. Since being diagnosed, have you experienced
a. pain (neuropathy)? NO
b. unwanted weight loss? NO
c. nausea? YES
d. loss of appetite? YES
e. anxiety and/or depression YES?
3. How many medications were you prescribed in 1995 and do you remember what their
functions were? The protocol at the call was to watch people’s T cell count, and as their T
cell level got low, then start them on medication; for the first 2 years I was not on
medication at all. In 1997 I got involved in a clinical trial for a protease inhibitor.
4. Did you experience any side effects when taking these medications? If so, what were the
side effects?
When I got involved in the protease clinical trial is when I started having the side effects.
The anxiety and depression was more about the HIV diagnosis in general; but nausea,
loss of appetite, diarrhea, lots of gastrointestinal upset that was a direct result of the
protease inhibitor I was taking. They were very hard to take, I was on them for a couple
years and I had nausea every day. They were very large, huge, and there were 16 of them.
Timing was also an issue, you had to take them exactly when to take them, you could not
really miss by even an hour. I took 8 in the morning and 8 at night plus all the other
drugs. Some pills had to be refrigerated, some couldn't be refrigerated, some required
food in your system, some required an empty stomach. I was taking well over 20 pills a
day and 16 of them were horse pills, and they made you feel horrible. I was having a
pavlovian response even before taking them, just looking at them made me feel like I was
going to throw up because they made me feel so terrible. Life was completely scheduled
around your medications.
5. How long after you were diagnosed did you pursue using marijuana to treat yourself and
what led you to do so?
I was a recreational pot user forever, and I was using pot at the time recreationally.
Medical marijuanna in the 90’s was like “no, no one would ever agree to that,” and it
seemed like a joke. I made the connection that it could be used, just a small puff before I
took them and I would feel so much better.
6. What changed after you began using marijuanna, symptom-wise?
I was able to get my medications down and I would be able to manage the nausea. My
experience proved that marijuana as a medicine is a real thing, it’s not a joke. It's helping
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me stay on my meds and it's helping me get through my day because there's nothing
worse than feeling nauseous all the time and you don't feel like eating. The stomach
calmed my stomach down so I wasn’t in such distress all the time. I could eat and tolerate
the medication.
7. How much medical marijuana do you consume at a time and when would you smoke?
I smoked the old fashioned way, the leaf through a little “one-hitter pipe” that I would
pack up and it was just one puff to feel immediate relief of the nausea and anticipated
nausea right before taking the medication. It really was just a little bit, there was no need
to get “toasted.” It was amazing.
8. How do you think taking medicinal marijuanna had an affect on your HIV prognosis?
I wouldn’t have been able to make it if I never figured it out. I could definitely see myself
not being able to maintain the regimen and maintain resistance to a possible AIDS
diagnosis so it really was incredibly important to have that tool because it's a very
schizophrenic state to be in. After starting on the trial I immediately started seeing the
numbers, T cells immediately went up, and my markers of health were great. “The drugs
were working this is fantastic, HIV is being suppressed, but I felt like hell.” I’ve been
positive since 1995, but those 2 years were the worst years of my life.
9. Do you believe that because you began using marijuana that you were able to avoid
prolonging the disease to AIDs?
Definitely. It maintained my health. I never ever got AIDS. I never had my T cell count
to be super dangerous because I was able to take my medications. It's a combination of
things, I had access to care and had doctors who were really embedded in the HIV
epidemic since the beginning. However, in terms of physically being able to take my
medication those first few years before switching to other drugs, marijuana was
absolutely critical. I can say that without a doubt and I’m really grateful that I just figured
it out.
10. And are there particular strands that you prefer, and why? I like the ones that are more
upbeat. I don't like ones that mellow you out and put you to sleep.
11. Currently, how many medications do you take for HIV-1? Side effects?
I am treatment experienced so my doctor had to make an interesting combination. I am
currently taking three medications: etravirine (non-nucleoside reverse transcriptase
inhibitor), Selzentry (CCR5 antagonist), and Tivicay (integrase inhibitor). I don't really
have any noticeable side effects. My stomach was never the same after the protease
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inhibitor drug but it's tolerable. I'm happy with it, my viral load remains suppressed to
undetectable levels. Currently, my T cell count is within a normal range.
12. What are your thoughts on modifying your genome to prevent HIV-1 proliferation in
your body?
I think it's really interesting! I’m all about new technology and research, especially things
that can suppress HIV and give people a better quality of life.
13. What are your thoughts on receiving a bone marrow transplant or a stem cell transplant
(adult or embryonic) to replace your hematopoietic system with blood cells immune to
HIV?
I think a bone marrow transplant is way too invasive and scary and it's way too much. I
appreciate what we’ve learned, but it's at a huge cost physically and in any way. I would
never be interested in anything that intense. If delivery was not through BMT there would
still be a lot of things I need to weigh, quality of life being the number one thing. I would
have to do a risk benefit of life to consider it.
9. PREVENTATIVE MEASURES
A. PRE- EXPOSURE PROPHYLAXIS (PREP)
People who do not have HIV but are at high risk of getting HIV (either through blood or semen)
take HIV medicine (PrEP) daily to reduce their chances of contracting HIV. Currently, the FDA
has approved 2 medications for HIV PrEP, Truvada and Descovy. PrEP reduces the risk of
getting HIV from sex by about 99% if 7 doses are taken per week (Anderson et al., 2012). The
CDC states that among people who inject drugs, PrEP reduces HIV risk by at least 74% when
taken daily (Pre-Exposure prophylaxis, 2019). Truvada and Descovy are combination medicines
containing tenofovir and emtricitabine (both HIV nucleoside reverse transcriptase inhibitors). Its
important to note that that while Truvada is recomended to prevent HIV for all people at risk
(sex and needle use), Descovy for PrEP is recomended to prevent HIV through sex excluding
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receptive vaginal sex (Pre-Exposure prophylaxis, 2019). Long term toxicity is still to be
determined although nausea has been noted in some patients taking HIV PrEP.
B. HIV VACCINE
In 2016, the National Institute of Health (NIH) and Partners launched the first HIV
vaccine efficacy trial in 7 years. The study, HVTN-702 (Uhambo), enrolled 5,400 HIV-negative
volunteers at 14 sites across South Africa (First New HIV Vaccine Efficacy Study in Seven
Years Has Begun, 2016). The study was targeted to prevent HIV infection in both men and
women. The HVTN 702 vaccine regimen consisted of two experimental vaccines. The first is a
canarypox vector-based vaccine (CPV), (ALVAC-HIV) that expresses gene products without
viral replication to prevent infection; the second is a two component gp120 protein subunit
vaccine with adjuvant to enhance the body’s immune response to the vaccine  (First New HIV
Vaccine Efficacy Study in Seven Years Has Begun, 2016). Both vaccines were modified from
the landmark RV144 clinical trial in Thailand from 2009 to be specific to HIV subtype C (most
common in the area). The study volunteers were randomized to either receive the vaccine or a
placebo, all of which will receive a total of five injections over one year (2016).
In February of 2020, the NIH discontinued HVTN-702 vaccinations because it was found
to not prevent HIV. The HVTN study actually received 6 injections over 18 months
(Experimental HIV Vaccine Regimen Ineffective in Preventing HIV, 2020). In January 2020 the
Data and Safety Monitoring Board (DSMB) examined the data. 2,694 participants received the
vaccine regimen and 2,689 received the placebo; after 60% of participants had been in the study
for more than 18 months it was found that 129 HIV infections occurred in the vaccine recipients
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and 123 HIV infections occurred in those who received the placebo (2020). Thus, the DSMB
concluded inefficacy.
In 2017, the National Institute of Health and Partners began a HIV vaccine efficacy study
that was targeted to prevent HIV acquisition among women. The study, Imbokodo, tests whether
an experimental vaccine prevents HIV among 2,600 HIV-negative women in 5 sub-Saharan
African countries (NIH and Partners Launch HIV Vaccine Efficacy Study, 2017). Of 1.8 million
new HIV infections worldwide in 2016, 43 percent were in eastern and southern Africa (girls and
women were disproportionately affected, near 60% of total) (NIH and Partners Launch HIV
Vaccine Efficacy Study, 2017). The vaccine was different from that of HVTN-702 as it was
modified for better efficiency and to target a wide variety of global HIV strains based on
“mosaic” immunogens. The study volunteers are randomized to either receive the vaccine or a
placebo, all of which will receive a total of four injections over one year; this includes 4 doses of
the quadrivalent mosaic vaccine as well as a combination on the last 2 doses with doses of HIV
protein clade C gp120 and aluminum phosphate adjuvant to boost immune response (2017).
Participants will be followed for two years and results should be announced later this year. In
preclinical studies, regimens with “mosaic-immunogen'' vaccines protected monkeys against
infection with an HIV-like virus (2017). Results are expected in 2021.
Similarly, in 2019, the National Institute of Health and Partners announced a phase 3 HIV
efficacy trial in multiple sites in North America, South America, and Europe (clade B HIV is
most common) (NIH and partners to launch HIV vaccine efficacy trial in the Americas and
Europe, 2019). The study, HPX3002/HVTN 706/ Mosaico is targeted to prevent HIV aquisition
among men who have sex with men and transgender people (2019). The study will enroll 3,800
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HIV-negative men and transgender people age 18-60. In the US, gay/bisexual men account for ⅔
of new HIV diagnoses and about 15% of transgender women have HIV. All participants were
offered PrEP and were randomized to receive the experimental vaccine or a placebo. Vaccines
are to be given four times a year and contain adenovirus (AD26) to deliver four mosaic
immunogens with the last two doses also containing doses of mosaic gp120 (different from
Imbokodo) and clade C gp120 proteins with aluminum phosphate (NIH and partners to launch
HIV vaccine efficacy trial in the Americas and Europe, 2019).
10. FUTURE OUTLOOKS
Human Immunodeficiency Virus 1 was chosen for this thesis because it’s evolutionary
intelligence and beauty. A virus is not living and therefore is only as good as its hosts. Many
people do not even know they have HIV until years after infection, since at first it only appears
as common flu-like symptoms or bacterial infections. HIV has evolved to keep its hosts and
therefore themselves alive for a very long time compared to other viruses.
HIV has so far defeated all attempts to completely eradicate it from the host’s genome.
HIV confounds the immune system in various ways. First and foremost it’s target, helper T cells.
T cells (both helper and killer) are recruited to fight millions of viral particles throughout the
course of one’s life, over the course of HIV infection, CD4 T cells deplete, and individuals are
no longer able to mount an effective immune response (dependent on treatment). Those left
untreated succumb to opportunistic infection but almost a decade after infection. Perhaps the
most evolved tactics of HIV are (1) reverse transcriptase’s high mutation rate that can cause viral
diversity in a single person (2) double receptor binding of gp120/gp41 complex and a
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chemokine receptor produces non-neutralizing antibodies that elicit non-neutralizing antibodies
(3) HIV carries host glycoproteins deemed “safe” from the immune system.
For those who are at high risk of exposure, PReP should be used to prevent infection. An
HIV vaccine is also underway. If unable to prevent, early detection is crucial with HIV detection.
HIV is detectable about 3 weeks after infection. It is extremely important to be tested for HIV if
there is probable cause of infection. 3 weeks is normally enough time for your body to build an
immune response. However, early testing can render a false negative, so testing again after a
week or two from the first test is the safest option.
ART drugs have so far been successful in suppressing viral loads to untransmissable
levels. However, as noted from the interview, many ART drugs have undesirable side effects that
can often cause one to veer off their medication regime. Medicinal marijuana has proven to help
ease the conditioned responses of the drugs as well as the effects of the virus itself. Pairing ART
drugs with medicinal marijuana can prove to be extremely beneficial. This combination is best
for now until genome editing and stem cell treatment can be applied for HIV. Furthermore, the
combination can be used for those who are against gene editing/cytotherapy for any reason.
Aside from ART drugs, gene silencing has proven to knock out different HIV proviral
sequences that stop HIV proliferation in vitro.  I f HIV infection is caught early, there is less
chance of HIV diversity in a single person, making the gRNA most effective. The issue using
RNAi, is that although transcription cannot occur for viral products to be made, a cell will
forever divide with the integrated provirus in its genome. The answer to this process is
CRISPR/Cas9 cutting HIV proviral segments from the host's genome. Over time, cells will
divide without the HIV until the CD4 T cells and all other cells infected are replaced. The ethical
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concerns about CRISPR/CAS 9 are not to be undermined. It’s also hard to imagine what the cost
of this therapy would be. However, it's impossible to deny its ability to cure hundreds of what
were once thought to be incurable diseases. Genome modification definitely needs an extreme
amount of regulation, but this biotechnology will find its way into common practices in due time.
Replacing one's hematopoietic system with HIV resistant blood cells (via homozygous
CCR5 delta 32 deletion) is the most effective practice in eradicating HIV. If a long-living
homozygous CCR5delta32 donor stem cell line can be made, HIV can be wiped out of thousands
of people in a short amount of time. Using this method is extremely beneficial in those who have
been diagnosed with HIV for many years because it disregards HIV’s high rate of mutagenicity.
Pairing stem cell treatments with gene editing can also be at high benefit. Making stem
hematopoietic cells immune to HIV can prove to be at more benefit than making NK cells prone
to killing HIV infected cells since HIV has many ways to evade immune system response.
PrEP is very effective in preventing HIV infection. Vaccine trials are fully underway that
carry various global strains. The best prevention with any sexually transmitted infection is
abstinence. However, if infected, one can live a long, happy, and healthy life with HIV. ART
drugs have evolutionized from 20 pills a day to possibly just one injection a month. However, it's
not to say HIV cannot mutate and become resistant to these drugs, or that the toxicity from these
drugs may not cause other complications later on. Plus, the fact of being HIV positive is a hard
burden for many to carry because it is still very stigmatized. The solution is completely
eradicating HIV either by CRISPR/CAS 9 genome modification or replacing the hematopoietic
system. These methods have proven to be successful in studies explained in this thesis (either
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in-vitro OR in-vivo). Despite the need for heavy regulation, it is safe to say that HIV infection
will soon be a curable disease with these biotechnological advances.
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